If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
BB will have access to 100 million doses of vaccines annually and commercialization rights of the SILS vaccine portfolio for global markets
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Subscribe To Our Newsletter & Stay Updated
